Pathology Diagnostics Ltd (PDL) Launches New Immunofluorescence Capabilities

Cambridge, United Kingdom, July 11, 2014 --(PR.com)-- Pathology Diagnostics has embraced the invaluably powerful technique of immunofluorescence (IMF); utilising fluorescent-labelled antibodies to detect specific target antigens. Used widely in both scientific research and clinical laboratories, the launch of IMF capabilities enables Pathology Diagnostics to continue increasing the high-level of services offered to its customer base.

The scope of immunofluorescence (IMF) capabilities in Pathology Diagnostics Ltd is perpetually growing and evolving, with the result that the technical team are able to perform single, double and an impressive triple IMF. With the addition of newly acquired fluorescence microscopy capabilities, Pathology Diagnostics is now able to perform triple IMF quantitative imaging with FITC, Texas Red, and DAPI channels. Double and/or triple staining reduces the amount of tissue required to get maximum information, which is of critical importance when dealing with miniscule and precious biopsy samples from early discovery and clinical trials studies.

Notes to editors and media:

Pathology Diagnostics Ltd is an independent GCLP accredited histopathology research organisation delivering high-quality tissue laboratory & diagnostics services to industry Research & Development scientists engaged in drug and biomarker development.

Specialising in the provision of clinical diagnostics and quantitative image analysis on human tissues for studies ranging from early discovery to clinical trials, Pathology Diagnostics offers a range of services from traditional histopathology techniques to advanced digital pathology, whole slide scanning, central biorepository services and quantitative image analysis of biomarkers.